Cargando…
Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy
[Image: see text] Synergistic drug combinations can extend the use of poly(ADP-ribose) polymerase inhibitors (PARPi) such as Olaparib to BRCA-proficient tumors and overcome acquired or de novo drug resistance. To identify new synergistic combinations for PARPi, we screened a “micro-library” comprisi...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Chemical Society
2023
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226041/ https://www.ncbi.nlm.nih.gov/pubmed/37185020 http://dx.doi.org/10.1021/acs.jmedchem.3c00322 |